항문암: 국가별 치료 선택지

임상시험 진행 중

• Chemoradiation with fluorouracil and mitomycin; radiation therapy; surgery for residual/recurrent disease; palliative surgery/radiation/chemoradiation; retifanlimab-dlwr (Zynyz) with carboplatin and paclitaxel; retifanlimab single agent임상시험임상시험Reported in a clinical trialUnited States · No biomarker requirement stated in fetched NCI/FDA sources; HPV association is disease biology context, not a treatment-selection claim here; Localized anal cancer chemoradiation; residual/recurrent anal canal cancer after nonoperative therapy; stage IV palliative contexts; first-line inoperable locally recurrent or metastatic SCAC; post-platinum locally recurrent or metastatic SCAC. · NCI PDQ is an evidence summary, not payer guidance. FDA approval notice does not determine individual eligibility, toxicity suitability, or reimbursement. Retifanlimab indication is for squamous cell carcinoma of the anal canal as stated by FDA. Confidence/conflicts: High for U.S. framework and retifanlimab approval; payer/implementation details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
• Chemoradiotherapy combinations including mitomycin with fluorouracil or capecitabine; carboplatin plus paclitaxel; FOLFCIS; docetaxel; immunotherapy options including nivolumab, pembrolizumab, or retifanlimab as second-line options in the draft-scope context임상시험임상시험InvestigationalUnited Kingdom · No biomarker requirement stated in fetched NICE draft scope; Chemoradiotherapy for anal canal cancer; inoperable anal canal cancer systemic chemotherapy; second-line post-chemotherapy immunotherapy draft-scope context. · NICE draft scope is not final NICE guidance or an MHRA label. The statement is useful for UK pathway context only; final reimbursement and recommendation status need separate verification. Confidence/conflicts: Medium because source is draft scope, not final guidance; final NICE/MHRA status remains active gap. NICE — technology appraisal draft scope
• Retifanlimab plus carboplatin/paclitaxel; KFA115 plus pembrolizumab임상시험 · NCT04472429임상시험Trial only (registry)Japan · No biomarker requirement stated for POD1UM-303 SCAC record; broad KFA115 study may have cohort-specific criteria; Locally advanced or metastatic SCAC; selected advanced cancer cohort including anal cancer. · Registry records do not establish PMDA approval, reimbursement, routine access, or individual eligibility. POD1UM-303 is completed; KFA115 is a broad phase 1 cohort. Confidence/conflicts: High for Japan registry-listed anal cancer activity; local approval/access unverified. ClinicalTrials.gov — clinical-trial registry
• Vobramitamab duocarmazine; KFA115 plus pembrolizumab; BI 754091 alone or with BI 836880임상시험 · NCT05551117임상시험Trial only (registry)Korea · No biomarker requirement stated in fetched Korea records; Advanced anal cancer cohort; advanced anal canal squamous cell carcinoma. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Two selected Korea records are terminated or withdrawn, and broad cohort studies require confirmation of anal cancer-specific enrollment. Confidence/conflicts: Medium-high for Korea registry-listed activity; current access is limited/uncertain. ClinicalTrials.gov — clinical-trial registry
• CRTE7A2-01 TCR-T cell therapy after fludarabine/cyclophosphamide and interleukin-2; PD-1 inhibitor plus concurrent chemoradiotherapy; toripalimab with chemotherapy followed by concurrent immunoradiotherapy임상시험 · NCT05122221임상시험Trial only (registry)China · HPV-16 positive status required for CRTE7A2-01 TCR-T study; HPV-16 positive advanced anal cancer; stage I-III anal canal/anal squamous cell carcinoma; locally advanced SCCA. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment, or individual eligibility. HPV-16 positivity and protocol-specific staging requirements must be confirmed. Confidence/conflicts: High for China registry-listed anal cancer study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
• Stimotimagene copolymerplasmid plus ganciclovir임상시험 · NCT05578820임상시험Trial only (registry)Russia · No biomarker requirement stated in fetched Russia record; Broad tumor-type study including anus neoplasms. · Registry record does not establish Russian regulator approval, reimbursement, routine access, current availability, or anal cancer-specific enrollment at each site. Confidence/conflicts: Medium for Russia broad anus-neoplasm registry activity; anal cancer-specific access unverified. ClinicalTrials.gov — clinical-trial registry